Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. 2010

Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan 250021, PR China.

Hepatocyte growth factor (HGF) and its receptor c-Met have been known as key determinants of growth and angiogenesis in some brain tumors like gliomas, meningiomas, and schwannomas. But little is known about their expression in pituitary adenomas. In this study, the expression of HGF and c-Met in pituitary adenomas of different histology types was investigated by immunohistochemistry, and correlative analysis of their expression with microvessel density (MVD), Ki-67 expression, and other clinicopathologic factors was made. The results showed that the expression of HGF and c-Met exists in 98% (64 of 65) and 92% (60 of 65) pituitary adenomas, respectively, and co-expression of them existed in 91% (59 of 65) adenomas. HGF had significant correlation with MVD (Spearman's correlation coefficient, r = .31, P = .01) and Ki-67 (r = .32, P = .01). c-Met had significant correlation with MVD (r = .30, P = .02) and Ki-67 (r = .38, P = .00). HGF and c-Met expression had no significant correlation with age or extrasellar extension. There were no significant differences in HGF and c-Met expression between pituitary adenomas of different histology types. The results indicate that HGF and c-Met are widely expressed in pituitary adenomas, and their expression correlates with MVD and Ki-67 expression.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D017228 Hepatocyte Growth Factor Multifunctional growth factor which regulates both cell growth and cell motility. It exerts a strong mitogenic effect on hepatocytes and primary epithelial cells. Its receptor is PROTO-ONCOGENE PROTEINS C-MET. Hepatopoietin,Hepatopoietin A,Scatter Factor,Factor, Hepatocyte Growth,Factor, Scatter,Growth Factor, Hepatocyte
D017404 In Situ Hybridization, Fluorescence A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei. FISH Technique,Fluorescent in Situ Hybridization,Hybridization in Situ, Fluorescence,FISH Technic,Hybridization in Situ, Fluorescent,In Situ Hybridization, Fluorescent,FISH Technics,FISH Techniques,Technic, FISH,Technics, FISH,Technique, FISH,Techniques, FISH
D019394 Ki-67 Antigen A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells. Antigen Ki-67,MIB-1 Antigen,Antigen Ki67,Antigen Ki 67,Antigen, Ki-67,Antigen, MIB-1,Ki 67 Antigen,Ki-67, Antigen,Ki67, Antigen,MIB 1 Antigen

Related Publications

Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
August 1994, Journal of hepatology,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
September 1998, Leukemia research,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
June 2000, Biology of reproduction,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
August 1995, The American journal of pathology,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
November 1996, Blood,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
July 2006, Acta oto-laryngologica,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
October 2001, International journal of oncology,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
December 1996, The Journal of endocrinology,
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
April 1997, Hepatology (Baltimore, Md.),
Xian-Zeng Hou, and Wei Liu, and Hai-Tao Fan, and Bin Liu, and Bo Pang, and Tao Xin, and Shang-Chen Xu, and Qi Pang
October 1995, The American journal of pathology,
Copied contents to your clipboard!